In a partnership with a US laboratory, Vetanco launched the new Circo/MycoGard vaccine in the Argentine and Latin American markets to immunize pigs against Porcine circovirus type 2 (PCV-2) and Mycoplasma hyopneumoniae.
The Argentine laboratory Vetanco established a commercial partnership with the US Pharmgate Animal Health company to distribute the Circo/MycoGard vaccine in Argentina and Latin America. The vaccine protects pigs against both PCV-2 and Mycoplasma hyopneumoniae.
The Circo/MycoGard vaccine enhances pig immunity against these diseases of worldwide distribution and high productive impact, especially on weight gain and mortality.
PCV-2 causes post-weaning multisystemic wasting syndrome and dermatitis-nephropathy syndrome.
In addition, the vaccine protects pigs against Enzootic pneumonia (EP), which is why it is considered a double-purpose vaccine.
“This vaccine was developed to protect the growth development of pigs. Farmers can rely on its strength, efficacy, and cutting-edge technology to fight the diseases from weaning to finishing,” said Gustavo Orella, technical sales coordinator for Latin America of Vetanco’s Pig Division.
The vaccine was launched virtually with the slogan “Circo/MycoGard Operation” on April 20 and counted with the presence of industry experts. Manuel Carbonell of Pharmgate Mexico spoke about the vaccine’s effectiveness; and Jeffrey Hall, Vetanco USA R&D Director, explained the vaccine production technology. Joaquim Segalés, researcher and professor at the Veterinary School of the Autonomous University of Barcelona, Spain, detailed the impacts caused by the diseases this vaccine fights.
Raúl Brega, Vetanco’s Cattle, Pigs, and Pets sales manager, presented the Circo/MycoGard vaccine. He highlighted that the partnership of the Argentine laboratory with Pharmgate Animal Health “established a synergy between both laboratories, which have more than 25 years of experience and presence in the global market.”
Circo/MycoGard Features
The vaccine protects from the moment of administration to slaughter, and promotes herd immunity. It is a one-dose vaccine, bottled in 50-, 100-, or 250-mL vials (1 mL/dose).
“Vaccination with 1 mL of Circo/MycoGard protected pigs from weaning to finishing, and promoted similar immunity performance compared with another commercial vaccine, and better pig performance than the controls,” pointed out Manuel Carbonell of Pharmgate Mexico.
Jeffrey Hall, R&D Director at Vetanco USA, explained that “considering the negative impact of some proteins included in vaccine composition, Pharmgate developed a purification step in the manufacturing of Circo/MycoGard. The use of a more recent sequence of PCV-2 subtype b (PCV-2 genotype b) also differentiates Circo/Mycogard from other products, protecting the pigs during the entire production cycle.”
Joaquim Segales of the School of Veterinary Medicine of the Autonomous University of Barcelona pointed out that “PCV-2 vaccines work very well provided they are correctly applied. Such vaccines have changed the epidemiology of this virus. Therefore, we need to monitor PCV-2 infections and adapt vaccination protocols by applying optimal vaccination strategies in order to balance passive immunity levels, management practices, and times of infection.”
Segales also said that “the basic diagnostic principles have not changed, but we must ensure they are correctly used. There are multiple PCV-2 genotypes, and the most frequently found today are PCV-2 d>, PCV-2 b>, and PCV-2ª.”
The final Q&A round was moderated by DVM Gustavo Orella, technical sales manager for Latin America of Vetanco’s Pig Division, and DVM Alberto Armocida, Vetanco’s Pig Division technical sales assistant.
